Hepatitis C Virus (HCV) RNA genotyping test is an advanced molecular diagnostic assay that identifies the specific genetic genotype and subtype of the hepatitis C virus present in a patient's blood. This testing service plays a critical role in clinical decision-making, treatment strategy optimization, and epidemiological surveillance. In this comprehensive guide, we cover the technical principles, sample requirements, testing methodologies, clinical applications, and frequently asked questions about HCV RNA genotyping.
Technical Overview
Hepatitis C Virus (HCV) is a positive-sense, single-stranded RNA virus belonging to the Flaviviridae family. Due to the lack of proofreading activity in its RNA-dependent RNA polymerase, HCV exhibits remarkable genetic heterogeneity. Based on nucleotide sequence divergence, HCV is classified into seven confirmed genotypes (Genotypes 1 through 7), which are further subdivided into more than 67 confirmed subtypes (such as 1a, 1b, 2a, 3a, and 6a).
The HCV RNA genotyping test is a nucleic acid-based molecular assay that analyzes conserved and variable regions of the viral genome—most commonly the 5' untranslated region (5'UTR), the core region, and the NS5B region—to determine the infecting genotype and subtype. Because HCV genotypes differ significantly in geographic distribution, disease progression patterns, and historical response rates to interferon-based therapies, accurate genotyping has long been a cornerstone of hepatitis C management and remains valuable for epidemiological tracking, resistance surveillance, and specific clinical scenarios.
- Genetic Targets: 5'UTR, core gene, E1, and NS5B regions of the HCV genome
- Classification Range: Genotypes 1–7 with major subtype differentiation
- Analytical Approach: Molecular amplification combined with sequence analysis or hybridization-based probe technology
- Clinical Significance: Supports treatment planning, resistance monitoring, and infection source tracing
Testing Samples
Serum
Serum is one of the most widely accepted sample types for HCV RNA genotyping. A venous blood sample of 3–5 mL should be collected in a sterile tube without anticoagulant. After clotting and centrifugation, the serum should be separated within 2 hours of collection to prevent degradation of viral RNA by cellular nucleases. Serum samples should be transported at 2–8°C and tested within 72 hours, or stored at -70°C for long-term preservation.
Plasma
Plasma collected in EDTA anticoagulant tubes is the preferred sample type for many molecular laboratories. Heparinized plasma is not recommended because heparin is a potent inhibitor of PCR amplification and may cause false-negative results. Plasma should be separated by centrifugation at low temperature and handled under the same transport and storage conditions as serum to maintain RNA integrity.
Sample Quality Requirements
- Prior confirmed HCV RNA positivity with a viral load typically above 1,000 IU/mL is recommended for reliable genotyping results
- Samples must be free of hemolysis and microbial contamination
- Repeated freeze-thaw cycles should be strictly avoided to prevent RNA degradation
- Sample tubes must be clearly labeled with patient identification and collection date
Testing Items
The HCV RNA genotyping service encompasses several core analytical components that together deliver a complete molecular profile of the infecting virus:
- HCV RNA Qualitative Confirmation: Verification of active viral replication prior to genotyping
- Genotype Identification: Determination of the major genotype (1–7) through sequence or probe-based analysis
- Subtype Differentiation: Discrimination of clinically relevant subtypes such as 1a versus 1b, particularly important for certain treatment regimens and resistance-associated substitution assessment
- Mixed Infection Detection: Identification of concurrent infection with multiple HCV genotypes where methodology allows
- Sequence Report: Provision of raw sequence data and phylogenetic analysis for reference laboratory or research applications
Testing Methods
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
RT-PCR is the foundational technology for HCV genotyping. Viral RNA is first reverse-transcribed into complementary DNA (cDNA), which is then amplified using genotype-specific or universal primers targeting conserved genome regions. Genotype assignment is achieved through amplified fragment size polymorphism analysis or subsequent sequencing of the amplicon. RT-PCR offers high sensitivity and a rapid turnaround time, making it suitable for routine clinical diagnostics.
Direct Sequencing (Sanger Sequencing)
Nucleotide sequencing of PCR amplicons from the 5'UTR, core, or NS5B regions represents the reference standard for HCV genotyping. The resulting sequences are compared with reference databases and analyzed phylogenetically to assign genotype and subtype with high confidence. Sequencing of the NS5B or core region provides superior subtype resolution compared with 5'UTR analysis alone, as the 5'UTR is highly conserved and may not reliably distinguish certain subtypes.
Line Probe Assay (LiPA)
The reverse hybridization line probe assay immobilizes genotype-specific oligonucleotide probes on membrane strips. Biotinylated PCR products from the 5'UTR and core regions are hybridized with these probes, and the resulting colorimetric banding pattern is interpreted to determine genotype and subtype. LiPA is standardized, easy to interpret, and widely validated for clinical use, though it may occasionally fail to identify rare or novel subtypes.
Real-Time PCR with Genotype-Specific Probes
Real-time PCR platforms utilize genotype-specific fluorescent probes or melting curve analysis to differentiate HCV genotypes in a closed-tube system. This method minimizes contamination risk, shortens turnaround time, and enables quantitative assessment, though its discriminatory capacity for uncommon subtypes is more limited than sequencing.
Next-Generation Sequencing (NGS)
NGS provides deep sequencing coverage of the HCV genome, enabling simultaneous genotype determination, subtype characterization, detection of mixed genotypes, and identification of resistance-associated substitutions such as NS5A Y93H and NS5B S282T. Although NGS is more resource-intensive, it is increasingly adopted by reference laboratories for complex cases and comprehensive resistance profiling.
Applications
- Treatment Strategy Optimization: Although modern pangenotypic direct-acting antivirals (DAAs) have reduced the routine need for genotyping, genotype data remain essential when using genotype-specific regimens such as glecaprevir/pibrentasvir duration adjustments or sofosbuvir/velpatasvir in specific contexts
- Resistance Surveillance: Baseline genotype and subtype information supports assessment of resistance-associated substitutions that may affect DAA efficacy, particularly in Genotype 3 infection
- Epidemiological Studies: Genotyping data illuminate transmission networks, geographic distribution patterns, and evolutionary dynamics of HCV in defined populations
- Clinical Prognosis Assessment: Certain genotypes, notably Genotype 3, are associated with accelerated fibrosis progression, steatosis, and increased hepatocellular carcinoma risk, informing intensified monitoring strategies
- Infection Source Tracing: Phylogenetic comparison of sequences assists public health investigations of outbreak clusters and transmission events
- Research Applications: Genotype-annotated samples support vaccine development, antiviral drug research, and viral pathogenesis studies
FAQ
Who should undergo HCV RNA genotyping testing?
Patients with confirmed active HCV infection (HCV antibody positive with detectable HCV RNA) are candidates for genotyping, particularly when genotype-specific treatment regimens are considered, when baseline resistance assessment is needed, when infection with an uncommon genotype is suspected, or when epidemiological investigation is warranted.
How long does it take to receive results?
Standard genotyping workflows typically deliver results within 3–7 working days after sample receipt. Complex cases requiring NGS analysis or repeat sampling may require additional turnaround time.
Is fasting required before sample collection?
No, fasting is not required for HCV RNA genotyping. The test detects viral genetic material and is not affected by recent food intake. Standard venipuncture precautions apply.
Why might genotyping fail even though HCV RNA is positive?
Genotyping failure can occur when the viral load is below the analytical threshold of the genotyping assay, when sequence variation in primer or probe binding regions prevents amplification, or when RNA has degraded during transport or storage. In such cases, a repeat sample or an alternative methodology such as NGS may be recommended.
Is genotyping still necessary in the era of pangenotypic DAAs?
While pangenotypic regimens have simplified treatment for many patients, genotyping remains valuable in specific situations, including suspected Genotype 3 infection with cirrhosis, assessment of resistance-associated substitutions, retreatment decisions after DAA failure, and public health surveillance programs. Clinicians should evaluate the need for genotyping on a case-by-case basis according to current clinical guidelines.
What does a mixed genotype result mean?
A mixed genotype result indicates concurrent infection with more than one HCV genotype, which may occur in people who inject drugs or those with repeated exposure risks. Mixed infections can complicate treatment response evaluation and may warrant resistance testing and tailored therapeutic management.
